Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor

被引:27
作者
Licht-Murava, Avital [1 ]
Plotkin, Batya [1 ]
Eisenstein, Miriam [2 ]
Eldar-Finkelman, Hagit [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
[2] Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel
关键词
protein kinase; molecular modeling; structure/function; inhibitors; drug design; parasite GSK-3; GLYCOGEN-SYNTHASE KINASE-3; INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE; PEPTIDE INHIBITORS; DRUG TARGET; PHOSPHORYLATION; GSK3; GLYCOGEN-SYNTHASE-KINASE-3; SPECIFICITY; MECHANISM;
D O I
10.1016/j.jmb.2011.02.036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A molecular understanding of substrate recognition of protein kinases provides an important basis for the development of substrate competitive inhibitors. Here, we explored substrate recognition and competitive inhibition of glycogen synthase kinase (GSK)-3 beta using molecular and computational tools. In previous work, we described Gln89 and Asn95 within GSK-3 beta as important substrates binding sites. Here, we show that the cavity bordered by loop 89-QDKRFICN-95, located in the vicinity of the GSK-3 beta catalytic core, is a promiscuous substrate binding subsite. Mutations within this segment highlighted Phe93 as an additional essential contact residue for substrates' recognition. However, unlike Gln89 and Asn95, Phe93 was also important for the binding of our previously described substrate competitive inhibitor, L803 [KEAPPAPPQS(p)P], and its cell-permeable variant L803-mts. The effects of the substitution of charged or polar residues within L803 further suggested that binding to GSK-3 beta is governed by hydrophobic interactions. Our computational model of GSK-3 beta bound to L803 was in agreement with the experimental data. It revealed L803 binding with a hydrophobic surface patch and identified interactions between Pro8 (L803) and Phe93 (GSK-3 beta). Computational modeling of new L803 variants predicted that inhibition would be strengthened by adding contacts with Phe93 or by increasing the hydrophobic content of the peptide. Indeed, the newly designed L803 variants showed improved inhibition. Our study identified different and overlapping elements in GSK-3 beta substrate and inhibitor recognition and provides a novel example for model-based rational design of substrate competitive inhibitors for GSK-3. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:366 / 378
页数:13
相关论文
共 50 条
  • [31] Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor
    Nisha, Chaluveelaveedu Murleedharan
    Kumar, Ashwini
    Vimal, Archana
    Bai, Bhukya Mounika
    Pal, Dharm
    Kumar, Awanish
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2016, 65 : 100 - 107
  • [32] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells
    Abdul, Ata Ur Rahman Mohammed
    De Silva, Bhagya
    Gary, Ronald K.
    BIOLOGY OPEN, 2018, 7 (01):
  • [33] GSK-3 inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice
    Huang, Sammen
    Wang, Haitao
    Turlova, Ekaterina
    Abussaud, Ahmed
    Ji, Xiang
    Britto, Luiz R.
    Miller, Steven P.
    Martinez, Ana
    Sun, Hong-Shuo
    Feng, Zhong-Ping
    CNS NEUROSCIENCE & THERAPEUTICS, 2017, 23 (05) : 405 - 415
  • [34] GSK-3 inactivation or depletion promotes β-cell replication via downregulation of the CDK inhibitor, p27 (Kip1)
    Stein, Jeffrey
    Milewski, Wieslawa M.
    Hara, Manami
    Steiner, Donald F.
    Dey, Arunangsu
    ISLETS, 2011, 3 (01) : 21 - 34
  • [35] MiR-135a inhibitor alleviates pulmonary arterial hypertension through β-Catenin/GSK-3β signaling pathway
    Yu, R-H.
    Wang, L-M.
    Hu, X-H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (21) : 9574 - 9581
  • [36] P24, a glycogen synthase kinase 3 (GSK 3) inhibitor
    Martín, CP
    Vázquez, J
    Avila, J
    Moreno, FJ
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1586 (01): : 113 - 122
  • [37] Binding of BIS like and other ligands with the GSK-3β kinase: a combined docking and MM-PBSA study
    Jena, Nihar R.
    JOURNAL OF MOLECULAR MODELING, 2012, 18 (02) : 631 - 644
  • [38] Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo
    Tapia-Rojas, Cheril
    Schueller, Andreas
    Lindsay, Carolina B.
    Ureta, Roxana C.
    Mejias-Reyes, Cristobal
    Hancke, Juan
    Melo, Francisco
    Inestrosa, Nibaldo C.
    BIOCHEMICAL JOURNAL, 2015, 466 : 415 - 430
  • [39] 4-Aminoethylamino-emodin - a novel potent inhibitor of GSK-3β - acts as an insulin-sensitizer avoiding downstream effects of activated β-catenin
    Gebhardt, Rolf
    Lerche, Katja S.
    Goetschel, Frank
    Guenther, Robert
    Kolander, Jens
    Teich, Lars
    Zellmer, Sebastian
    Hofmann, Hans-Joerg
    Eger, Kurt
    Hecht, Andreas
    Gaunitz, Frank
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (06) : 1276 - 1293
  • [40] 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
    Poloznikov, Andrey
    Nikulin, Sergey
    Bolotina, Larisa
    Kachmazov, Andrei
    Raigorodskaya, Maria
    Kudryavtseva, Anna
    Bakhtogarimov, Ildar
    Rodin, Sergey
    Gaisina, Irina
    Topchiy, Maxim
    Asachenko, Andrey
    Novosad, Victor
    Tonevitsky, Alexander
    Alekseev, Boris
    FRONTIERS IN PHARMACOLOGY, 2021, 12